NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study-Reference-Cited by-同舟云学术

NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study

Published:2024-01-04 Issue:2 Volume:51 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Garufi Alessia¹,Pettinari Riccardo²,Monteonofrio Laura¹,Puliani Giulia³,Virdia Ilaria¹,Appetecchia Marialuisa³,Marchetti Fabio⁴,Cirone Mara⁵,Soddu Silvia¹,D'Orazi Gabriella¹

Affiliation:

1. Unit of Cellular Networks and Molecular Therapeutic Targets, IRCCS Regina Elena National Cancer Institute, I-00144 Rome, Italy

2. Chemistry Interdisciplinary Project (CHIP), School of Pharmacy, University of Camerino, I-62032 Camerino (MC), Italy

3. Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, I-00144 Rome, Italy

4. Chemistry Interdisciplinary Project (CHIP), School of Science and Technology, University of Camerino, I-62032 Camerino (MC), Italy

5. Department of Experimental Medicine, Sapienza University of Rome, Laboratory Affiliated to Pasteur Institute Italy Foundation Cenci Bolognetti, I-00161 Rome, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Reference66 articles.

1. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms;Rindi;Endocr Pathol,2022

2. Gastroenteropancreatic neuroendocrine tumors;Cives;CA Cancer J Clin,2018

3. Changes in the epidemiology of neuroendocrine tumours;Huguet;Neuroendocrinology,2017

4. Surgery for primary pancreatic neuroendocrine tumors;Norton;J Gastrointest Surg,2006

5. Treatment options for pancreatic neuroendocrine tumors;Akirov;Cancers,2019